Kpc Mouse Model
Kpc Mouse Model - Related Videos
09:18
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
0 Views •
2026
This protocol uses a multichamber bed for parallel magnetic resonance imaging (MRI) of up to four animals to detect pancreatic adenocarcinoma tumors in genetically engineered mouse models. This multianimal MRI protocol is fast and cost-effective for detecting and measuring tumors, facilitating animal selection for preclinical studies and longitudinal monitoring of tumor growth.
06:24
Mouse Models of Periventricular Leukomalacia
0 Views •
Cited by 28 •
2010
We established mouse models of periventricular leukomalacia (PVL), the predominant brain injury in premature infants characterized by periventricular white matter lesions. Hypoxia/ischemia with/without systemic infection are the primary causes of PVL. Unilateral carotid ligation and hypoxia exposure with/without lipopolysaccharide injection creates PVL-like lesions in P6 mice.
08:23
In Vitro Modeling of Cancerous Neural Invasion: The Dorsal Root Ganglion Model
0 Views •
Cited by 10 •
2016
This video article shows the use of the dorsal root ganglia (DRG)/cancer cell model in pancreatic ductal adenocarcinoma.
06:51
A Preclinical Murine Model of Hepatic Metastases
0 Views •
Cited by 119 •
2014
A preclinical, murine model of hepatic metastases performed via a hemispleen injection technique.
07:37
Mouse Models for Graft Arteriosclerosis
0 Views •
Cited by 17 •
2013
We describe protocols for our mouse graft arteriosclerois (GA) models which involve interposition of a mouse vessel segment into a recipient of the same inbred strain. By backcrossing additional genetic changes into the vessel donor, the model can assess the effect of specific genes on GA.
FAQs
The model’s genetic logic couples pancreatic lineage targeting with two cancer-driving alterations. Pdx1-Cre activates oncogenic KrasG12D and mutant Trp53R172H in pancreatic progenitor cells, so transformation begins in the tissue where pancreatic tumors arise rather than in an unrelated transplant site. This design connects defined molecular events with subsequent lesion formation, invasion, and metastatic progression for mechanistic study.
Pdx1-Cre provides the pancreatic progenitor-cell context in which the engineered alleles become active. KrasG12D and Trp53R172H supply the oncogenic and mutant tumor-suppressor alterations that initiate the model’s cancer program. Their combination allows researchers to examine how specified genetic events relate to the transition from precursor lesions to invasive pancreatic tumors and later metastatic disease.
Tumors arising in native pancreatic tissue retain the local setting in which cancer develops and progresses. This makes it possible to study interactions between malignant cells and the surrounding tumor microenvironment, including stromal remodeling and immune suppression. The same context also supports investigation of treatment resistance, which may be difficult to capture when tumor cells are studied outside their original tissue environment.
Progression from precursor lesions to invasive tumors creates a time-dependent framework for examining pancreatic cancer at multiple stages. Researchers can relate tumor initiation to later stromal remodeling, metastatic progression, and immune suppression rather than observing only a final tumor state. This staged development helps connect biological changes with mechanisms that contribute to poor outcomes and resistance to treatment.
Researchers can apply candidate drugs or treatment combinations within a model that includes developing tumors and their native microenvironment. The resulting studies can address whether an intervention affects pancreatic tumor progression, treatment resistance, or other disease-relevant features. Because the model progresses over time, it also supports evaluation of therapeutic effects in relation to changing tumor and stromal conditions.
KPC mice are especially useful for questions spanning pancreatic tumor initiation, cancer cell interactions with the tumor microenvironment, immune suppression, and metastatic progression. The model also supports studies of biomarkers and mechanisms underlying poor clinical outcomes. Its value is greatest when investigators need to connect defined genetic changes with evolving tumor behavior in pancreatic cancer.
Studies can use this model to examine tumor development, stromal remodeling, metastatic progression, immune suppression, and resistance to treatment. It can also support assessment of drug candidates, combination therapies, and biomarkers. These outcomes provide a broader view than tumor growth alone by linking therapeutic responses and disease features to the biological environment in which pancreatic cancer develops.